Detail akcie Novo Nord Br/Rg-B online

Business Summary: Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Novo Nordisk A/S revenues increased 13% to DKR175.31B. Net income increased 25% to DKR69.55B. Revenues reflect EUCAN segment increase of 19% to DKR37.12B. Net income benefited from Rare disease segment income increase of 52% to DKR1.62B. Dividend per share remained flat at DKR3.75. Basic Earnings per Share excluding Extraordinary Items increased from DKR12.50458 to DKR15.66173.